China Grand Pharmaceutical Reports Robust 2023 Revenues and Pipeline Advancements
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has reported its financial results...
Dr. Reddy’s Launches Biosimilar Versavo in UK to Challenge Roche’s Cancer Therapy Avastin
Dr. Reddy’s Laboratories (NYSE: RDY), a prominent Indian pharmaceutical company, has launched its biosimilar Versavo...
Bayer’s Elinzanetant Achieves Primary Endpoint in Late-Stage Menopause Symptom Trial
Bayer (ETR: BAYN), a leading German pharmaceutical company, has announced positive results from a placebo-controlled...
China Medical System Gets Green Light for Phase III Clinical Trial of Opzelura in Atopic Dermatitis
China Medical System Holdings (CMS; HKG: 0867) has received approval from the National Medical Products...
AstraZeneca’s Lynparza-Imfinzi Combo Shows Promising Results in Endometrial Cancer Study
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has presented interim results from a late-stage...
China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal
The National Joint Procurement Office in China has released a notification outlining the information and...
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results...
Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma
The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug...
Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma
The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio...
CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations
The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China,...
AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its...
Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is...
Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced...
Bio-Thera Solutions and SteinCares Ink Licensing Deal for LatAm Biosimilar Distribution
Bio-Thera Solutions (SHA: 688177), a Chinese biopharmaceutical company, has entered into a licensing agreement with...
C&Y Pharmaceutical Teams Up with GigaCeuticals to Form AI-Driven Drug Development JV
Shanxi C&Y Pharmaceutical Group Co., Ltd (SHE: 300254), a Chinese pharmaceutical company, is venturing into...
GSK’s Jemperli Shows Survival Benefits in Phase III Endometrial Cancer Study
GlaxoSmithKline (GSK; NYSE: GSK), a leading UK pharmaceutical company, has presented early results from a...
Akeso Biopharma Reports Record Revenue and First Profit, Driven by Innovative Drugs
Akeso Biopharma (HKG: 9926) has announced its financial results for 2023, reporting a record revenue...
uBriGene Partners with XJTLU to Develop CAR-NK Cell Therapies for Solid Tumors
uBriGene, a China-based biotechnology company, has entered into a partnership with Xi’an Jiaotong-Liverpool University (XJTLU)...
Boehringer Ingelheim Partners with Sosei Group to Develop GPR52 Agonists for Schizophrenia
Boehringer Ingelheim (BI), headquartered in Germany, has entered into a global collaboration and exclusive option-to-license...
BeiGene’s Tislelizumab Receives FDA Approval for Esophageal Squamous Cell Carcinoma
BeiGene (NASDAQ: BGNE) has announced that the US Food and Drug Administration (FDA) has granted...